Investors

News Releases

Date	Title
Aug 28, 2018	Summary Toggle RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Aug 15, 2018	Summary Toggle RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors
Aug 14, 2018	Summary Toggle RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
Aug 7, 2018	Summary Toggle RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
Aug 2, 2018	Summary Toggle RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan
Aug 1, 2018	Summary Toggle RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring
Jun 28, 2018	Summary Toggle BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury
May 18, 2018	Summary Toggle RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts
May 11, 2018	Summary Toggle RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors
May 10, 2018	Summary Toggle RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

Investors